Investigating cardiovascular effects of immune checkpoint inhibitors in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the mechanisms behind atherosclerotic plaque instability in patients receiving immune checkpoint inhibitors (ICIs) for various cancers. It will involve a prospective pilot approach, comparing surrogate markers of vascular toxicity and circulating biomarkers before and after ICI treatment. The study will utilize arterial Doppler measurements to assess flow-mediated reserve, a key indicator of endothelial function. By understanding these mechanisms, the research seeks to shed light on the cardiovascular risks associated with ICIs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients scheduled for first ICI therapy at our institution;
* Matched controls with cancer and no ICI therapy;

Exclusion Criteria:

* Major cardiovascular event in the past 6 months;
* Unable to provide informed consent;
* History of ICI therapy

Where it's running

• INstitut Mutualiste Montsouris
  Paris, France Recruiting

Study contacts

• Study coordinator: Isabelle Sauret, MBS
• Email: isabelle.sauret@imm.fr
• Phone: +33 1 56 61

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Comparing two radiation therapy techniques for advanced solid tumors

  This study is testing whether a new type of radiation therapy works better than the standard method for treating advanced solid tumors that have spread, to see if it can improve outcomes for patients needing palliative care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05837767

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.